Relmada Therapeutics
Relmada Therapeutics
RLMD
NASDAQ
0.27
USD
0.00%
About
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist.
Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 60.7K |
| Three Month Average Volume | 2.3M |
| High Low | |
| Fifty-Two Week High | 7.2225 USD |
| Fifty-Two Week Low | 1.88 USD |
| Fifty-Two Week High Date | 04 Mar 2024 |
| Fifty-Two Week Low Date | 12 Aug 2024 |
| Price and Volume | |
| Current Price | 2.8 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -26.38% |
| Thirteen Week Relative Price Change | -12.80% |
| Twenty-Six Week Relative Price Change | -62.55% |
| Fifty-Two Week Relative Price Change | -33.89% |
| Year-to-Date Relative Price Change | -42.89% |
| Price Change | |
| One Day Price Change | 6.06% |
| Thirteen Week Price Change | -6.67% |
| Twenty-Six Week Price Change | -58.82% |
| Five Day Price Change | 1.08% |
| Fifty-Two Week Price Change | -17.16% |
| Year-to-Date Price Change | -32.37% |
| Month-to-Date Price Change | -23.50% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.83586 USD |
| Book Value Per Share (Most Recent Quarter) | 2.03789 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.83586 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 2.03789 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.03153 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.2822 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.88031 USD |
| Normalized (Last Fiscal Year) | -3.2822 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.2822 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.88031 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.2822 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.88031 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.20021 USD |
| Cash Per Share (Most Recent Quarter) | 2.33436 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.28221 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.56565 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.59929 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 29.95% |
| EPS Change (Trailing Twelve Months) | 32.81% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -70,437,330 |
| Net Debt (Last Fiscal Year) | -96,323,860 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 8 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -51,659,210 |
| Free Cash Flow (Trailing Twelve Months) | -48,180,620 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -78.89% |
| Return on Assets (Trailing Twelve Months) | -89.88% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -87.51% |
| Return on Equity (Trailing Twelve Months) | -100.40% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -87.51% |
| Return on Investment (Trailing Twelve Months) | -100.40% |
| Return on Investment (5 Year) | -99,999.99% |